Duality Advisers LP purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 18,718 shares of the biopharmaceutical company’s stock, valued at approximately $1,440,000.
Several other institutional investors also recently bought and sold shares of GILD. Capital Research Global Investors grew its position in Gilead Sciences by 12.7% in the first quarter. Capital Research Global Investors now owns 95,982,319 shares of the biopharmaceutical company’s stock worth $7,175,643,000 after acquiring an additional 10,849,434 shares in the last quarter. Capital International Investors boosted its holdings in shares of Gilead Sciences by 336.8% in the 1st quarter. Capital International Investors now owns 56,369,657 shares of the biopharmaceutical company’s stock worth $4,214,200,000 after purchasing an additional 43,464,551 shares in the last quarter. Capital World Investors boosted its holdings in shares of Gilead Sciences by 123.0% in the 1st quarter. Capital World Investors now owns 46,331,318 shares of the biopharmaceutical company’s stock worth $3,463,732,000 after purchasing an additional 25,555,467 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Gilead Sciences by 3.4% during the 1st quarter. Geode Capital Management LLC now owns 19,882,508 shares of the biopharmaceutical company’s stock valued at $1,484,311,000 after purchasing an additional 658,471 shares during the last quarter. Finally, Legal & General Group Plc raised its holdings in shares of Gilead Sciences by 2.6% during the 1st quarter. Legal & General Group Plc now owns 8,496,358 shares of the biopharmaceutical company’s stock valued at $634,826,000 after buying an additional 216,005 shares in the last quarter. Hedge funds and other institutional investors own 78.74% of the company’s stock.
In other Gilead Sciences news, CAO Diane E. Wilfong sold 12,264 shares of the firm’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $80.09, for a total transaction of $982,223.76. Following the completion of the sale, the chief accounting officer now directly owns 23,685 shares in the company, valued at approximately $1,896,931.65. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Brett A. Pletcher sold 13,210 shares of the firm’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $79.23, for a total transaction of $1,046,628.30. Following the sale, the executive vice president now owns 27,204 shares of the company’s stock, valued at $2,155,372.92. The disclosure for this sale can be found here. Over the last three months, insiders sold 28,079 shares of company stock worth $2,240,630. Insiders own 0.13% of the company’s stock.
NASDAQ:GILD opened at $69.53 on Friday. The company has a debt-to-equity ratio of 1.00, a current ratio of 3.04 and a quick ratio of 2.92. The firm’s 50-day moving average price is $75.47 and its 200-day moving average price is $73.57. The company has a market capitalization of $87.22 billion, a PE ratio of -289.70, a P/E/G ratio of 2.34 and a beta of 0.70. Gilead Sciences, Inc. has a 1-year low of $60.89 and a 1-year high of $85.97.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.11 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.46). Gilead Sciences had a positive return on equity of 32.17% and a negative net margin of 1.16%. The business had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.24 billion. Equities analysts anticipate that Gilead Sciences, Inc. will post 6.79 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be issued a $0.68 dividend. This represents a $2.72 annualized dividend and a yield of 3.91%. Gilead Sciences’s dividend payout ratio (DPR) is 44.30%.
A number of brokerages have recently issued reports on GILD. TheStreet cut shares of Gilead Sciences from a “b” rating to a “c” rating in a research note on Thursday. UBS Group lowered shares of Gilead Sciences from a “buy” rating to a “neutral” rating and upped their price target for the company from $77.00 to $80.00 in a research report on Monday, April 27th. BMO Capital Markets lowered Gilead Sciences from an “outperform” rating to a “market perform” rating and set a $79.00 target price for the company. in a research note on Monday, April 20th. Cantor Fitzgerald restated a “buy” rating and set a $86.00 target price on shares of Gilead Sciences in a report on Friday. Finally, BidaskClub cut Gilead Sciences from a “sell” rating to a “strong sell” rating in a research note on Friday, July 24th. Four investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $79.63.
Gilead Sciences Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Featured Story: Leveraged Buyout (LBO) Explained
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.